HOME >> BIOLOGY >> NEWS
UCSD discovery opens new avenues for design of anti-tumor medications

ors were starved of oxygen and nutrients, resulting in tumors were smaller in size than in normal mice and had dead tissue at their centers.

To date, most efforts to develop angiogenesis inhibitors--drugs to prevent growth of blood vessels-- have focused on inhibiting the signals sent out by the tumor in response to low oxygen. These latest findings suggest that targeting the endothelial cells' response to low oxygen is a viable alternative strategy to the development of angiogenesis inhibitors. Furthermore, the researchers point out that it may be easier to design effective treatments that target the endothelial cells rather than the tumor cells.

"Cancer cells mutate frequently," says Nan Tang, a graduate student working with Johnson and the first author on the paper. "This means that it is common for these cells to develop resistance to drugs. On the other hand, the endothelial cells are normal cells and would be much less likely to develop drug resistance."

"The endothelial cells are also in direct contact with the blood, simplifying the delivery of drugs," adds Tang.

Because HIF-1alpha is usually turned off in endothelial cells, and the mice lacking the gene in blood vessels were healthy and had normal lifespans, the researchers think that inhibiting the blood vessels' response to low oxygen should be relatively safe. One caveat is that interfering with blood vessels' response to low oxygen may also inhibit wound healing, as was observed in the mice lacking HIF-1alpha. According to the researchers, further work will be needed before their discovery can be applied to actually design new anti-tumor drugs.

"Since the response of the blood vessels to low oxygen likely involves multiple genes and chemical signals, we still need to tease apart the steps involved in the response," says Johnson. "It will also be important to understand how the signals sent out by the tumor, to stimulate t
'"/>

Contact: Kim McDonald
kmcdonald@ucsd.edu
858-534-7572
University of California - San Diego
15-Nov-2004


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. New proteomics research promises to revolutionize biomedical discovery
3. MU researchers make discovery in molecular mechanics of phototropism
4. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
5. Screening approach leads to discovery of gene linked to breast cancer
6. Lucky 13 as new gene discovery offers further hope for childhood blindness
7. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
8. Biting discovery: MU entomologist finds host of new aquatic insect species in Thailand
9. J&JPRD discovery may lead to new treatments for chronic sensitivity, pain caused by cold
10. Protein enables discovery of quantum effect in photosynthesis
11. Unicellular microRNA discovery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCSD discovery opens new avenues for design anti tumor medications

(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
(Date:4/21/2015)... April 21, 2015 The North ... in 2014 to $605.1 million by 2019, at a ... Browse through the TOC of North ... of the industry trends and segments, with help of ... Early buyers will receive 10% customization ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... PROVO, Utah , April 21, 2015  Tute Genomics, ... the hiring of Josh Forsythe as VP of ... that has witnessed a significant expansion in its commercial operations ... " Josh Forsythe is a ... Robison , MD MBA, CEO of Tute Genomics. "Josh,s vast ...
(Date:4/21/2015)... York (PRWEB) April 21, 2015 Progyny, ... Fertility Authority, LLC, announced that it has secured additional ... (KPCB), TPG Biotech, SR One and Merck Serono Ventures. ... to provide patients the best fertility outcomes by aligning ... the largest online marketplace for families seeking fertility solutions ...
Breaking Biology Technology:North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2
Cached News: